← brief for 2026-11-02 · Slowing decline

SGLT2 inhibitors in chronic kidney disease.

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

This review summarizes major trials showing that SGLT2 drugs protect the kidneys. It covers both people with and without diabetes. The article also looks at how these drugs might help people on dialysis. It is a guide for doctors to feel confident starting this therapy for kidney care.

Who did this work

Yau AA · Bajaj A · Rizvi A · Li J · Kaur T

Source

Paper · PubMed, the drug frontier · 2026 Nov 2
https://pubmed.ncbi.nlm.nih.gov/42969253/